Kim YH, Bagot M, Pinter-Brown L, et al. Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. ASH 59th Annual Meeting & Exhibition, abstract 817.
Beïnvloedt overgewicht het veiligheidsprofiel van nivolumab?
mrt 2023 | Dermato-oncologie, Hoofd-halsoncologie, Immuuntherapie, Longoncologie, Lymfoom, Maag-darm-leveroncologie, Uro-oncologie